CELLINK´s commercialized technology featured on the cover of Science Magazine

CELLINK has partnered with Volumetric to commercialize the Lumen X Bioprinting platform in March 2019. Research conducted with the Lumen X technology platform is featured on the front page of Science Magazine Vol. 364, Issue 6439 and scientific breakthroughs achieved with the technology is published in the journal.

In the Science Magazine publication led by Dr. Bagrat Grigoryan, the Lumen X platform successfully created functional vascular networks and demonstrated significant potential to enhance the study of intervascular transport, nutrient delivery, host engraftment and more. 

The circulatory and pulmonary systems in air-breathing vertebrates contain intertwining networks of vessels that do not intersect with each other, and reproducing these structures has been a major challenge for many bioprinters. 

CELLINK partnered with Texas-based startup Volumetric earlier this year to commercialize the Lumen X, a bioprinter that leverages more than one million points of light to construct microscopic features with speed, fidelity and precision. CELLINK, the world’s first bioink company and the global leader in bioprinters and bioinks, continually seeks new partnerships to provide researchers with emerging capabilities and innovations in the field. 

For more information, please contact: 

Erik Gatenholm, CEO                                                Gusten Danielsson, CFO
Phone: EU +46 73 267 00 00                                     Phone: +46 70 991 86 04
US +1 (650) 515 5566                                                US+1 (857) 332 2138
Email:eg@cellink.com                                                Email:gd@cellink.com  

About CELLINK

CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at: certifiedadviser@penser.se.

About Us

Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,600 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com/investors

Subscribe

Documents & Links